A drug once approved as an antihistamine in Russia improved thinking processes and ability to function in patients with Alzheimer's disease in a study conducted there, said an expert at Baylor College of Medicine in Houston. The findings are published in the journal The Lancet.
"More research is needed, but we are encouraged by the effect the drug Dimebon had on Alzheimer's patients," said Dr. Rachelle Doody, professor of neurology at BCM and lead author of the study. In the study, the authors noted that Dimebon is the first drug for Alzheimer's disease that demonstrated continued improvement in patients over a 12 month period. Other approved drugs do not have this effect.
- read the release [1]
Related Articles:
Medivation touts Phase II data on Huntington's therapy [2]
Medivation forges $100M deal to fund trial [3]
Medivation shares jump on Alzheimer's data [4]
Links:
[1] http://www.fiercebiotech.com/press-releases/alzheimers-drug-reverses-cognitive-decline-over-12-month-period-early-human-testing
[2] http://www.fiercebiotech.com/story/medivation-touts-phase-ii-data-huntington-s-therapy/2008-07-08
[3] http://www.fiercebiotech.com/story/medivation-forges-100m-deal-fund-trial/2007-09-10
[4] http://www.fiercebiotech.com/story/medivation-shares-jump-on-alzheimer-s-data/2006-09-21?utm_source=related&utm_medium=internal